公开(公告)号：US20220175771A1

公开(公告)日：2022-06-09

申请号：US17529609

申请日：2021-11-18

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH

IPC: A61K31/501 ,  A61K9/00 ,  A61K9/20 ,  A61K31/4412 ,  A61K31/4436 ,  A61K31/4468 ,  A61K31/496 ,  A61K31/5377 ,  G01N33/68

Abstract: The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancer. Some aspects of this disclosure provide treatment modalities, methods, strategies, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers, dependent upon EZH2 (enhancer of zeste 2 polycomb repressive complex 2) function with an EZH2 inhibitor.

公开(公告)号：US20220105098A1

公开(公告)日：2022-04-07

申请号：US17474202

申请日：2021-09-14

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH ,  Michael THOMENIUS

IPC: A61K31/5377 ,  A61K9/00 ,  A61P35/00 ,  A61K45/06

Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

公开(公告)号：US20240139203A1

公开(公告)日：2024-05-02

申请号：US18462229

申请日：2023-09-06

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH ,  Michael THOMENIUS

IPC: A61K31/5377 ,  A61K9/00 ,  A61P35/04

CPC classification number: A61K31/5377 ,  A61K9/0019 ,  A61K9/0053 ,  A61P35/04

Abstract: The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.

公开(公告)号：US20190328743A1

公开(公告)日：2019-10-31

申请号：US16310597

申请日：2017-06-16

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH ,  Michael THOMENIUS

IPC: A61K31/5377 ,  A61P35/00 ,  A61K9/00

Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

公开(公告)号：US20240180919A1

公开(公告)日：2024-06-06

申请号：US18496074

申请日：2023-10-27

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH ,  Michael THOMENIUS

IPC: A61K31/5377 ,  A61K9/00 ,  A61P35/00

CPC classification number: A61K31/5377 ,  A61K9/0053 ,  A61P35/00 ,  A61K45/06

Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

公开(公告)号：US20220160721A1

公开(公告)日：2022-05-26

申请号：US17515979

申请日：2021-11-01

Applicant: Epizyme, Inc.

Inventor： Jesse SMITH ,  Heike KEILHACK ,  Scott RIBICH

IPC: A61K31/5377 ,  A61P35/00 ,  A61K31/4412 ,  A61K9/00 ,  A61K31/551 ,  A61K31/553 ,  A61K31/496 ,  G01N33/574 ,  A61K31/4545 ,  A61K31/5386 ,  A61K31/4439 ,  A61K31/4433 ,  A61K45/06

Abstract: The disclosure relates to a method for treating cancer comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the cancer is characterized by at least one cancer cell originating from a stem cell, a progenitor cell, or an immature cell and wherein the at least one cancer cell comprises one or more genetic lesion(s) that confer(s) dependence of the cancer cell on an EZH2 function. In certain embodiments, the EZH2 inhibitor of the disclosure is tazemetostat or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190038633A1

公开(公告)日：2019-02-07

申请号：US16075855

申请日：2017-02-08

Applicant: Epizyme, Inc.

Inventor： Jesse SMITH ,  Heike KEILHACK ,  Scott RIBICH

IPC: A61K31/5377 ,  A61P35/00 ,  A61K31/4412 ,  A61K31/496 ,  A61K31/551 ,  A61K31/553 ,  A61K9/00

Abstract: The disclosure relates to a method for treating cancer comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the cancer is characterized by at least one cancer cell originating from a stem cell, a progenitor cell, or an immature cell and wherein the at least one cancer cell comprises one or more genetic lesion(s) that confer(s) dependence of the cancer cell on an EZH2 function. In certain embodiments, the EZH2 inhibitor of the disclosure is tazemetostat or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220288085A1

公开(公告)日：2022-09-15

申请号：US16306182

申请日：2017-06-01

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH ,  Michael THOMENIUS

IPC: A61K31/5377 ,  A61P35/04 ,  A61K9/00

Abstract: The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.

公开(公告)号：US20200323865A1

公开(公告)日：2020-10-15

申请号：US16789815

申请日：2020-02-13

Applicant: Epizyme, Inc.

Inventor： Jesse SMITH ,  Heike KEILHACK ,  Scott RIBICH

IPC: A61K31/5377 ,  A61P35/00 ,  A61K31/4412 ,  A61K9/00 ,  A61K31/551 ,  A61K31/553 ,  A61K31/496 ,  G01N33/574 ,  A61K31/4545 ,  A61K31/5386 ,  A61K31/4439 ,  A61K31/4433 ,  A61K45/06

Abstract: The disclosure relates to a method for treating cancer comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the cancer is characterized by at least one cancer cell originating from a stem cell, a progenitor cell, or an immature cell and wherein the at least one cancer cell comprises one or more genetic lesion(s) that confer(s) dependence of the cancer cell on an EZH2 function. In certain embodiments, the EZH2 inhibitor of the disclosure is tazemetostat or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190350929A1

公开(公告)日：2019-11-21

申请号：US16482748

申请日：2018-02-02

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH

IPC: A61K31/501 ,  A61K31/4468 ,  A61K31/4436 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/4412 ,  A61K9/00 ,  A61K9/20 ,  G01N33/68

Abstract: The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancer. Some aspects of this disclosure provide treatment modalities, methods, strategies, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers, dependent upon EZH2 (enhancer of zeste 2 polycomb repressive complex 2) function with an EZH2 inhibitor.